A step towards treating KRAS-mutant NSCLC

摘要

During the past few years, oncologists have witnessed the rectification of non-small-cell lung cancer (NSCLC) as not one disease, but several molecularly defined subsets of disease. The largest subset harbours an activating KRAS mutation and includes about 25% of all patients with lung cancer, mainly adenocarcinoma. Other less common genetically defined subsets of NSCLC, including those with EGFR or ALK activating mutations, show high sensitivity to tyrosine-kinase inhibitors such that patients frequently have sustained clinical responses to therapy.23 By contrast, KRAS has remained an elusive target for cancer therapy.